Importance

Loading Importance Indicators...

Abstract

Peritoneal dialysis fluid comprising a compound that inhibits the activity of glycogen synthase kinase (GSK) -3 in particular activity (GSK) -3b for use in the prevention of infectious and non-infectious complications such as peritonitis, injury, damage and failure of the peritoneal membrane, barrier dysfunction and detachment of mesothelial cells. Claim 2: Peritoneal dialysis fluid according to claim 1, characterized in that the peritoneal dialysis fluid is selected from the group consisting of carbohydrate-based dialysis fluids and amino acid-based dialysis fluids. Claim 4: Peritoneal dialysis fluid according to any of the preceding claims, characterized in that the peritoneal dialysis fluid is based on icodextrin. Claim 11: Peritoneal dialysis liquid or compound according to any of the preceding claims, characterized in that the compound that inhibits glycogen synthase kinase (GSK) -3 activity is selected from the group consisting of lithium, tideglusib, NP-103, GSK-3b inhibitor I (TDZD-8, 4-benzyl-2-methyl-1,2,4-thiadiazolidino-3,5-dione), GSK-3b inhibitor II (2-thio (3-iodobenzyl) -5- (1-pyridyl) - [1,3,4] -oxadiazole), inhibitor IV of GSK-3 (SB-216763, 3- (2,4-dichlorophenyl) -4- (1-methyl-1H-indole-3 -il) -1H-pyrrole-2,5-dione), inhibitor IX of GSK-3 (BIO, (2Z, 3E) -6-bromoindirubin-3-oxime), inhibitor VI of GSK-3b (2-chlor- 1- (4,5-dibromo-thiophene-2-yl) -ethanone), inhibitor VII of GSK-3b (2,4-dibromoacetophenone), inhibitor VIII of GSK-3b (AR A014418, N- (4-methoxybenzyl) -N- (5-nitro-1,3-thiazol-2-yl) urea), GSK-3 inhibitor X (BIO-acetoxime, (2Z, 3E) -6-bromoindirubin-3-acetoxime), XI inhibitor of GSK-3b (3- (1- (3-hydroxypropyl) -1H-pyrrolo [2,3-bipyridin-3-yl] -4-pyrazin-2-yl-pyrrole-2,5 -diona, 7AIPM), inhibitor XIII of GSK-3b (5-methyl-1H-pyrazol-3-yl) - (2-phenylquinazolin-4-yl) amine), inhibitor XII of GSK-3b (TWS119, ditrifluoroacetate 3 - [6- (3-aminophenyl) -7H-pyrrolo [2,3-d] pyrimidin-4-yl] oxyphenol), inhibitor XVIII of GSK-3b (2- (chloro-4- (4-thiophene-2-) il-pyrimidin-2-ylamino) -phenyl) - (4-methyl-piperazin-1-yl) -methanone), GSK-3b X inhibitor (BIO-acetoxyme, (2Z, 3E) -6-bromoindirubin-3- acetoxime), inhibitor XI of GSK-3b (3- (1- (3-hydroxypropyl) -1H-pyrrolo [2,3-b] pyridin-3-yl] -4-pyrazin-2-yl-pyrrole-2, 5-dione, 7AIPM), inhibitor XIX of GSK-3b (IM-12, C₂₂H₂₀FN₃O₂, derived from indolylmaleimide), inhibitor XVI of GSK-3 (6- (2-4- (2,4-dichlorophenyl) -5- ( 4-methyl-1H-imidazol-2-yl) -pyrimidin-2-ylamino) ethylamino) -nicotinonitrile, CHIR99021), inhibitor XVII of GSK-3 (5-benzylamino-3-oxo-2,3-dihydro-1, 2,4-thiadiazole, TDZD-20), inhibitor XXIII of GSK-3, compound A (6-methyl-N - {[3 - [[3- (1-methylethoxy) propyl] carbamoyl] -1H-pyrazole-4 -yl] pyridin-3-carboxamide), inhibitor XXIII of GSK-3b, 3F8 (5-ethyl-7,8-dimethoxy-1H-pyrrolo [3,4-c] -isoquinolin-1,3- (2H) -djone), peptide inhibitor GSK-3b (L803, HKEAPPAPPQSpP-NH₂), inhibitor of the peptide GSK-3b (L803-mts, Myr-NGKEAPPAPPQSpP-NH₂), GF-109203X (2- [1- (3-dimethylaminopropyl) indole-3-yl] -3- (indole-3-yl) maleimide) and its pharmaceutically acceptable salts and mixtures.

Loading the Abstract Image...

First Claim

Family

Loading Family data...

• 15 United States
• 10 France
• 8 Japan
• 7 China
• 5 Korea
• 2 Other